1 April 2023 false No description of principal activity Taxfiler 2024.5 12517848business:PrivateLimitedCompanyLtd2023-04-012024-03-31 125178482023-03-31 125178482023-04-012024-03-31 12517848business:AuditExempt-NoAccountantsReport2023-04-012024-03-31 12517848business:FilletedAccounts2023-04-012024-03-31 125178482024-03-31 12517848business:Director12023-04-012024-03-31 12517848business:RegisteredOffice2023-04-012024-03-31 125178482023-03-31 12517848core:WithinOneYear2024-03-31 12517848core:WithinOneYear2023-03-31 12517848core:AfterOneYear2024-03-31 12517848core:AfterOneYear2023-03-31 12517848core:ShareCapitalcore:PreviouslyStatedAmount2024-03-31 12517848core:ShareCapitalcore:PreviouslyStatedAmount2023-03-31 12517848core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-03-31 12517848core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-03-31 12517848core:PreviouslyStatedAmount2024-03-31 12517848core:PreviouslyStatedAmount2023-03-31 12517848business:SmallEntities2023-04-012024-03-31 12517848countries:EnglandWales2023-04-012024-03-31 12517848core:MotorVehicles2023-03-31 12517848core:ComputerEquipment2023-03-31 12517848core:MotorVehicles2024-03-31 12517848core:ComputerEquipment2024-03-31 12517848core:MotorVehicles2023-04-012024-03-31 12517848core:ComputerEquipment2023-04-012024-03-31 12517848core:AdditionsToInvestments2024-03-31 125178482022-04-012023-03-31 iso4217:GBP xbrli:pure
Company Registration No. 12517848 (England and Wales)
Diabetes And Endocrine Health Ltd Unaudited accounts for the year ended 31 March 2024
Diabetes And Endocrine Health Ltd Unaudited accounts Contents
Page
- 2 -
Diabetes And Endocrine Health Ltd Company Information for the year ended 31 March 2024
Director
Dr Dulmini Kokilari Kathyana Kariyawasam
Company Number
12517848 (England and Wales)
Registered Office
131 South End C/O Aczone Consultants Ltd Croydon CR0 1BJ United Kingdom
- 3 -
Diabetes And Endocrine Health Ltd Statement of financial position as at 31 March 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Tangible assets
29,242 
38,991 
Investments
10,000 
- 
39,242 
38,991 
Current assets
Cash at bank and in hand
118,978 
12,479 
Creditors: amounts falling due within one year
(69,582)
(26,616)
Net current assets/(liabilities)
49,396 
(14,137)
Total assets less current liabilities
88,638 
24,854 
Creditors: amounts falling due after more than one year
(5,918)
(6,667)
Net assets
82,720 
18,187 
Capital and reserves
Called up share capital
100 
100 
Profit and loss account
82,620 
18,087 
Shareholders' funds
82,720 
18,187 
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 6 June 2024 and were signed on its behalf by
Dr Dulmini Kokilari Kathyana Kariyawasam Director Company Registration No. 12517848
- 4 -
Diabetes And Endocrine Health Ltd Notes to the Accounts for the year ended 31 March 2024
1
Statutory information
Diabetes And Endocrine Health Ltd is a private company, limited by shares, registered in England and Wales, registration number 12517848. The registered office is 131 South End, C/O Aczone Consultants Ltd, Croydon, CR0 1BJ, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
4
Tangible fixed assets
Motor vehicles 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 April 2023
49,590 
3,480 
53,070 
At 31 March 2024
49,590 
3,480 
53,070 
Depreciation
At 1 April 2023
12,398 
1,681 
14,079 
Charge for the year
9,299 
450 
9,749 
At 31 March 2024
21,697 
2,131 
23,828 
Net book value
At 31 March 2024
27,893 
1,349 
29,242 
At 31 March 2023
37,192 
1,799 
38,991 
5
Investments
Other investments 
£ 
Valuation at 1 April 2023
- 
Additions
10,000 
Valuation at 31 March 2024
10,000 
- 5 -
Diabetes And Endocrine Health Ltd Notes to the Accounts for the year ended 31 March 2024
6
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Bank loans and overdrafts
16,274 
21,443 
Taxes and social security
15,797 
- 
Other creditors
252 
252 
Loans from directors
36,009 
3,919 
Accruals
1,250 
1,002 
69,582 
26,616 
7
Creditors: amounts falling due after more than one year
2024 
2023 
£ 
£ 
Bank loans
5,918 
6,667 
8
Average number of employees
During the year the average number of employees was 1 (2023: 1).
- 6 -